Vietnam Drug Agency Says MNCs Increasingly Violate Rules
This article was originally published in PharmAsia News
Executive Summary
Vietnam's chief drug regulator accused multinational pharmaceuticals of increasingly violating the country's rules governing quality. The head of the Vietnam Pharmaceutical Management Department told a conference with the Health Ministry and foreign drug makers his agency counted 41 violations last year, compared with just 12 the previous year. Truong Quoc Cuong said 35 of the violations were committed by Indian drug makers. Vietnam now numbers 438 foreign pharmas operating in the country, up from 370 in 2007. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.